Evidence map›Paper›PMID 36717871›Full record

ArticleJournal of pharmaceutical policy and practice2023

Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda.

Ayo-Oley Baldeh, Colin Millard, Allyson M Pollock, Petra Brhlikova

Open access · goldAbstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
6.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Establishing links between drug registers and essential medicines lists.Bulletin of the World Health Organization · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Ayo-Oley BaldehInstitute of Population Health Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4AX, Tyne and Wear, UK.
Colin MillardInstitute of Population Health Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4AX, Tyne and Wear, UK. colin.millard@ncl.ac.uk.ORCID http://orcid.org/0000-0002-0055-7605
Allyson M PollockInstitute of Population Health Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4AX, Tyne and Wear, UK.
Petra BrhlikovaInstitute of Population Health Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4AX, Tyne and Wear, UK.
Institute of Population and Public Health · CACentre for Life · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEssential medicines (EMs) are those that satisfy the basic healthcare needs of the population. However, access to EMs remains a global health challenge. The World Health Organization (WHO) and the East African Community (EAC) manufacturing plan 2017-2027 support local production of EMs as a strategy to improve access to medicines. The aim of this study was to determine for each therapeutic class on the national essential medicine lists (NEMLs) of Kenya, Tanzania and Uganda, the number of EMs produced in each country.

methodsIn 2018, we analysed NEMLs and national drug registers (NDRs) in each country to identify local manufacturers and local products by EM status. For each local manufacturer we determined the number of EM products and individual EMs, and analysed EMs in each therapeutic class by registration status and whether produced locally.

resultsThere were nine companies manufacturing locally in Kenya, four in Tanzania and six in Uganda. Most local medicine products were non-EM products. Of the 946 locally produced products in Kenya, 310 were EM products; of the 97 locally produced products in Tanzania, 39 were EM products; and of the 181 locally produced products in Uganda, 100 were EM products. Many local EM products were duplicate. Only a small proportion of EMs on each NEML were produced locally: 21% (92/430) in Kenya, 5% (24/510) in Tanzania, and 10% (55/526) in Uganda. Kenya, Tanzania and Uganda had no local EM products in 13/32, 17/28 and 15/32 therapeutic classes, respectively. The proportion of EMs that were registered varied across the countries from 327 (76%) in Kenya, 269 (53%) in Tanzania, and 319 (60%) in Uganda.

conclusionsThis study highlights the importance of auditing NDRs and NEMLs for local production to inform regional and national local manufacturing strategies. EMs should be prioritized for local production and drug registration to ensure that production is aligned with local health needs.

Indexed as

Access to medicinesEast African CommunityEssential medicinesKenyaLocal productionLow-and-middle-income countriesMedicine registrationPublic healthTanzaniaUganda

Identifiers

PMID36717871
PMCPMC9886419
OpenAlexW4318586248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.